Author Archives: truemeds

Casein Kinase 1δ/ε: Casein Kinase 1 delta and epsilon (CK1δ/ε) have emerged as pivotal regulators of human biology, functioning as dynamic “molecular switches” that influence circadian rhythms, cancer progression, metabolic health, and neurological disorders. Their unique ability to alter substrate preference through autophosphorylation of the C-terminal tail allows CK1δ/ε to toggle between stabilizing and destabilizing […]

RMC-5127 represents a breakthrough in targeting one of cancer’s most elusive drivers—the KRAS G12V mutation. Developed by Revolution Medicines, this first-in-class small molecule selectively inhibits the active, GTP-bound form of KRAS through a unique tri-complex mechanism involving Cyclophilin A. Preclinical data show strong anti-tumor efficacy, oral bioavailability, and exceptional brain penetration, positioning RMC-5127 as a […]

Antibodies for Brain Organoid Research: Brain organoids have emerged as powerful 3D models that replicate key aspects of human brain development and disease. Antibodies are indispensable tools in this field, enabling precise identification of neural stem cells, neurons, glial cells, and synaptic structures. This blog highlights essential antibodies used in brain organoid research, including Nestin, […]

Artificial Intelligence in drug development: Artificial intelligence (AI) is playing an increasingly important role in drug development. It is applied in drug molecule design, metabolism prediction, and toxicology assessment to enhance research efficiency and reduce failure rates. Machine learning models help define structure–activity relationships, predict metabolic sites, and identify toxic metabolites. AI platforms such as […]

TNF and TNFSF: Tumor necrosis factor (TNF) and its superfamily (TNFSF) play central roles in immune regulation, inflammation, and cell death. Since their discovery, TNF-targeted therapies have become key treatments for autoimmune and inflammatory diseases. Advances in biotechnology have led to the development of FDA-approved TNF inhibitors and TNFSF-based biologics, including monoclonal antibodies, fusion proteins, […]